Cooley advised ERYTECH Pharma on its $143.7 million global offering of an aggregate of 6,180,137 ordinary shares, including the full exercise of the underwriters’ option to…
ERYTECH’s $144 Million Initial Public Offering
Cooley advised ERYTECH Pharma on its $143.7 million global offering of an aggregate of 6,180,137 ordinary shares, including the full exercise of the underwriters’ option to…